Sanofi’s (SNY) general medicines and emerging markets sub-segment includes revenues from established prescription products, generic products, and emerging markets. This sub-segment reported revenues of 433 million euros in 3Q17, representing a 0.9% YoY fall.
This decline in revenues was driven by lower sales from European markets but was substantially offset by strong sales from US markets and the rest of the world. Emerging markets reported nearly flat revenues for 3Q17.
The consumer healthcare business includes various products like allergy, cough and cold products, digestive products, nutritional products, and pain management products. The business reported revenues of 1.13 billion euros for 3Q17—a 48.5% YoY rise. This rise was driven by strong sales across all markets worldwide.
SNY’s pain management products reported revenues of 309 million euros in 3Q17, which was 50.5% higher YoY, driven by strong sales across all major markets.
Allergy, cough, and cold products reported revenues of 264 million euros for 3Q17, which was 52.8% higher YoY and was driven by strong sales of Nasacort and Allegra in all major markets outside the US. Digestive products reported revenues of 220 million euros in 3Q17, which was 97.4% higher YoY and was driven by strong sales across worldwide markets.
Nutritional products reported revenues of 162 million euros in 3Q17, which was 38% higher YoY and was driven by strong sales in across all major markets outside of the US.
Notably, the PowerShares International Dividend Achievers ETF (PID) has 9.0% of its total investments in healthcare companies, with 1.5% in Sanofi ADR (SNY), 1.3% in Novartis ADR (NVS), 1.0% in Novo Nordisk ADR (NVO), and 4.2% in Teva Pharmaceuticals ADR (TEVA).